Literature DB >> 22933424

Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study.

Jiunn-Horng Chen1, Wen-Harn Pan, Chih-Cheng Hsu, Wen-Ting Yeh, Shao-Yuan Chuang, Pin-Yu Chen, Hui-Chen Chen, Chwen-Tzuei Chang, Wei-Lun Huang.   

Abstract

OBJECTIVE: Hyperuricemia is the most important risk factor for the development of gout; however, not all patients with hyperuricemia develop gout, and patients experiencing a gout attack are not necessarily found to have hyperuricemia. We hypothesized that the interactions between serum uric acid (sUA) and other potential metabolic comorbidities increase the risk of gout development.
METHODS: A prospective study was conducted to link baseline metabolic profiles from the MJ Health Screening Center to gout outcomes extracted from the Taiwan National Health Insurance database. A Cox proportional hazards model was used to assess the metabolic risks for incident gout stratified by hyperuricemia status (sUA level >7 mg/dl or not).
RESULTS: During a mean followup period of 6.45 years (261,500 person-years), 1,189 patients with clinical gout (899 men, 202 women ages >50 years, and 88 women ages ≤50 years) were identified among the 40,513 examinees. The multivariate adjusted hazard ratios (HRs) of hyperuricemia for gouty arthritis were 5.80 (95% confidence interval [95% CI] 4.93-6.81) in men and 4.37 (95% CI 3.38-5.66) in women. Hypertriglyceridemia (triglyceride level >150 mg/dl) was found as an independent risk factor, with HRs of 1.38 (95% CI 1.18-1.60) in men with hyperuricemia and 1.40 (95% CI 1.02-1.92) in men without hyperuricemia. General obesity (body mass index >27 kg/m(2) ) was independently associated with gout in older women, with HRs of 1.72 (95% CI 1.15-2.56) in women with hyperuricemia and 2.19 (95% CI 1.47-3.26) in women without hyperuricemia.
CONCLUSION: General obesity in women and hypertriglyceridemia in men may potentiate an sUA effect for gout development. Further investigation is needed.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 22933424     DOI: 10.1002/acr.21824

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  19 in total

Review 1.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 2.  Prevention of rheumatic diseases: strategies, caveats, and future directions.

Authors:  Axel Finckh; Kevin D Deane
Journal:  Rheum Dis Clin North Am       Date:  2014-09-04       Impact factor: 2.670

Review 3.  Role of diet in hyperuricemia and gout.

Authors:  Abhijeet Danve; Shiv Tej Sehra; Tuhina Neogi
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-11-19       Impact factor: 4.098

Review 4.  Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies.

Authors:  Dagfinn Aune; Teresa Norat; Lars J Vatten
Journal:  Eur J Nutr       Date:  2014-09-11       Impact factor: 5.614

Review 5.  Comorbidities in patients with crystal diseases and hyperuricemia.

Authors:  Sebastian E Sattui; Jasvinder A Singh; Angelo L Gaffo
Journal:  Rheum Dis Clin North Am       Date:  2014-02-19       Impact factor: 2.670

6.  Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals.

Authors:  Mei Zhang; Xiaohui DI; Lin Xu; Juan Xu; Yongge Yang; Nan Jiang; Lixue Song; Xueting Xu
Journal:  Exp Ther Med       Date:  2013-11-19       Impact factor: 2.447

7.  Increased risk of a suicide event in patients with primary fibromyalgia and in fibromyalgia patients with concomitant comorbidities: A nationwide population-based cohort study.

Authors:  Chen-Chia Lan; Chun-Hung Tseng; Jiunn-Horng Chen; Joung-Liang Lan; Yu-Chiao Wang; Gregory J Tsay; Chung-Yi Hsu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

8.  The association of anthropometry indices with gout in Taiwanese men.

Authors:  Wen-Yu Lin; Chia-Chi Lung; Ting-Sung Liu; Zhi-Hong Jian; Pei-Chieh Ko; Jing-Yang Huang; Chien-Chang Ho; Shih-Chang Chen; Yi-Chen Chiang; Yung-Po Liaw
Journal:  BMC Endocr Disord       Date:  2013-08-15       Impact factor: 2.763

9.  Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.

Authors:  K-H Yu; J-H Lai; P-N Hsu; D-Y Chen; C-J Chen; H-Y Lin
Journal:  Scand J Rheumatol       Date:  2016-01-15       Impact factor: 3.641

10.  An Independent Risk of Gout on the Development of Deep Vein Thrombosis and Pulmonary Embolism: A Nationwide, Population-Based Cohort Study.

Authors:  Chien-Chung Huang; Po-Hao Huang; Jiunn-Horng Chen; Joung-Liang Lan; Gregory J Tsay; Hsiao-Yi Lin; Chun-Hung Tseng; Cheng-Li Lin; Chung-Yi Hsu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.